Skip to content

Released Nov 18, 2025, after the close

10-Q filed Nov 18, 2025, 49 days after period end · 0001213900-25-112095

Q3 2025 · 10-Q
Revenue—
Net Income-$46.16Kno prior Q3 2024 on fileN/M vs Q2 2025
EPS, diluted—
Operating Income-$155,513—
Operating Cash Flowderived-$690,726—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

no prior Q3 2024 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Drugs Made In America Acquisition II Corp. · CIK 2040475 · Engraved from SEC EDGAR